Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of experimental medicine Vol. 217; no. 9
Main Authors:	Koenig, Lars M, Boehmer, Daniel F R, Metzger, Philipp, Schnurr, Max, Endres, Stefan, Rothenfusser, Simon
Format:	Journal Article
Language:	English
Published:	United States Rockefeller University Press 07-09-2020
Subjects:	Betacoronavirus Coronavirus Infections - epidemiology COVID-19 Humans Infectious Disease and Host Defense Inflammation Innate Immunity and Inflammation Pandemics Pneumonia, Viral SARS-CoV-2 Viewpoint
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Commentary-3 content type line 23
ISSN:	0022-1007 1540-9538
DOI:	10.1084/jem.20201342